来自LPS预先条件的心肌细胞的大型细胞外囊泡通过调解巨细胞极化和调节p38 MAPK通路来缓解心肌炎
Yanjie Jiang1,2,3, Yingnan You1, Yaxue Xie1,3
1Department of Pediatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Frontiers in immunology
|September 25, 2025
概括
来自心肌细胞的细胞外囊泡 (EVs) 通过减少炎症和改善心脏功能,显示了心肌炎的治疗潜力. 这些EV通过输送PP2AA调节巨细胞极化,提供了一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 心肌炎涉及巨细胞和心肌细胞之间的细胞间通信中断.
- 细胞外囊泡 (EVs) 是细胞间通信的关键媒介.
- 心肌细胞衍生的EVs在心肌炎中的特定作用尚未完全理解.
研究的目的:
- 在病毒性心肌炎的小鼠模型中研究心肌细胞衍生的EVs的治疗效果.
- 阐明EV介导的巨细胞功能调节的潜在机制.
- 探索EVs作为心肌炎新治疗策略的潜力.
主要方法:
- 从LPS或PBS预先条件的心肌细胞中分离大型EV (C-lEVLPS/C-lEVPBS).
- 在病毒性心肌炎模型中对巨细胞和心脏功能的C-lEVLPS影响的体外和体内评估.
- 评估心脏功能,炎症,巨细胞两极分化和分子信号通路 (转录组学,蛋白质组学).
主要成果:
- 在小鼠模型中,C-lEVLPS显示出抗炎作用,缓解心脏炎症和功能障碍.
- C-lEVLPS促进了类似M2的巨细胞极化,同时抑制了M1的极化.
- C-lEVLPS被丰富了酸酶2支架子单元α (PP2AA),它去酸化p38.
结论:
- 心肌细胞衍生的EV (C-lEVLPS) 是心肌炎的一种有前途的治疗方法.
- 该机制涉及PP2AA从心肌细胞传递给巨细胞,调节p38 MAPK通路和巨细胞两极分化.
- 这项研究揭示了用于心肌炎治疗的新型EV介导通信途径.
相关概念视频
Myocarditis I: Introduction
374
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
374
Inflammation
61.7K
Overview
61.7K
Myocarditis III: Medical Management
175
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
175


